Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular DystrophyAnne M. Connolly, Ewa Carrier, Xueping Zhang et al.|Journal of Neuromuscular Diseases|2023Cited by 24
Pamrevlumab did not meet its primary endpoint for non-ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-1 trialAnne M. Connolly, Ewa Carrier, Brenda Wong et al.|medRxiv|2025Cited by 3
Pamrevlumab did not meet its primary endpoint for ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-2 trialBrenda Wong, H. Phan, Yann Péréon et al.|medRxiv|2025Cited by 2